{"id":8256,"date":"2025-12-19T11:21:37","date_gmt":"2025-12-19T10:21:37","guid":{"rendered":"https:\/\/www.seedcapitalbizkaia.eus\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/"},"modified":"2026-04-14T17:47:26","modified_gmt":"2026-04-14T15:47:26","slug":"innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro","status":"publish","type":"post","link":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/","title":{"rendered":"Innitius advances innovation in preterm birth assessment"},"content":{"rendered":"<p>The Biscayan company Innitius, owned by Seed Capital Bizkaia, has received authorisation from the Spanish Agency for Medicines and Health Products (<i>Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios<\/i> &#8211; AEMPS) to begin the international phase of a clinical study to evaluate the safety and predictive capacity of the CerviSense \u00ae TPTL device for diagnosing preterm birth.<\/p>\n<p>This new study is part of the FineBirth programme (funded by the European Union&#8217;s EIC Accelerator) and represents a crucial milestone toward CE marking and future clinical adoption of the device in Europe.<\/p>\n<p>Following the success of a pilot study with 100 patients that exceeded clinical targets in only a quarter of the expected time, the new trial will include 357 patients across hospitals in Spain and Germany under real-world clinical conditions to validate its efficacy and reliability.<\/p>\n<h3><b>CerviSense\u00ae TPTL, an innovation to assess the risk of preterm birth<\/b><\/h3>\n<p>CerviSense\u00ae TPTL, the innovative technology developed by Innitius, enables rapid assessment of the risk of spontaneous preterm delivery in pregnant women presenting symptoms of impending preterm delivery. It combines measurements of tissue elasticity with artificial intelligence models to provide accurate diagnoses in real time, supporting health professionals in decision-making during labour management.<\/p>\n<p>\u201cThis milestone is essential to bringing a precise and easy-to-use tool to market,&#8221; said <b>Rub\u00e9n Molina<\/b>, CEO and co-founder of Innitius. \u201cIt reinforces our commitment to clinical and regulatory robustness while expanding the programme internationally.\u201d<\/p>\n<h3><b>Seed Capital Bizkaia Fund I, supporting cutting-edge innovation<\/b><\/h3>\n<p>With <a href=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/investment-policy\/fund-i\/\">Fondo I,<\/a> Seed Capital Bizkaia participates in Innitius&#8217; innovative project.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Fondo I is one of the financing tools offered by Seed Capital Bizkaia to support innovative business initiatives that are in the early stages of development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.<\/p>\n","protected":false},"author":2,"featured_media":7990,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-8256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia<\/title>\n<meta name=\"description\" content=\"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia\" \/>\n<meta property=\"og:description\" content=\"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/\" \/>\n<meta property=\"og:site_name\" content=\"Seed Capital Bizkaia\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-19T10:21:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T15:47:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1096\" \/>\n\t<meta property=\"og:image:height\" content=\"588\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"seed.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"seed.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/\"},\"author\":{\"name\":\"seed.com\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/9f7fe51a3f998da35b8377c79e654262\"},\"headline\":\"Innitius advances innovation in preterm birth assessment\",\"datePublished\":\"2025-12-19T10:21:37+00:00\",\"dateModified\":\"2026-04-14T15:47:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/\",\"name\":\"Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png\",\"datePublished\":\"2025-12-19T10:21:37+00:00\",\"dateModified\":\"2026-04-14T15:47:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/9f7fe51a3f998da35b8377c79e654262\"},\"description\":\"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png\",\"contentUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png\",\"width\":1096,\"height\":588,\"caption\":\"innitius\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innitius advances innovation in preterm birth assessment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#website\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/\",\"name\":\"Seed Capital Bizkaia\",\"description\":\"Seed Capital Bizkaia\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/9f7fe51a3f998da35b8377c79e654262\",\"name\":\"seed.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g\",\"caption\":\"seed.com\"},\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/author\\\/seed-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia","description":"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/","og_locale":"en_US","og_type":"article","og_title":"Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia","og_description":"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.","og_url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/","og_site_name":"Seed Capital Bizkaia","article_published_time":"2025-12-19T10:21:37+00:00","article_modified_time":"2026-04-14T15:47:26+00:00","og_image":[{"width":1096,"height":588,"url":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png","type":"image\/png"}],"author":"seed.com","twitter_card":"summary_large_image","twitter_misc":{"Written by":"seed.com","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#article","isPartOf":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/"},"author":{"name":"seed.com","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/9f7fe51a3f998da35b8377c79e654262"},"headline":"Innitius advances innovation in preterm birth assessment","datePublished":"2025-12-19T10:21:37+00:00","dateModified":"2026-04-14T15:47:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/"},"wordCount":284,"image":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#primaryimage"},"thumbnailUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/","url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/","name":"Innitius advances innovation in preterm birth assessment - Seed Capital Bizkaia","isPartOf":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#primaryimage"},"image":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#primaryimage"},"thumbnailUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png","datePublished":"2025-12-19T10:21:37+00:00","dateModified":"2026-04-14T15:47:26+00:00","author":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/9f7fe51a3f998da35b8377c79e654262"},"description":"La empresa bizkaina Innitius, participada por Seed Capital Bizkaia, ha recibido la autorizaci\u00f3n de la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) para iniciar la fase internacional de un estudio cl\u00ednico que evaluar\u00e1 la seguridad y la capacidad predictiva del dispositivo CerviSense\u00ae TPTL para el diagn\u00f3stico del parto prematuro.","breadcrumb":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#primaryimage","url":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png","contentUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2025\/12\/Captura-de-Pantalla-2025-12-19-a-las-11.17.47.png","width":1096,"height":588,"caption":"innitius"},{"@type":"BreadcrumbList","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/innitius-avanza-en-la-innovacion-de-la-evaluacion-del-parto-prematuro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.seedcapitalbizkaia.eus\/en\/"},{"@type":"ListItem","position":2,"name":"Innitius advances innovation in preterm birth assessment"}]},{"@type":"WebSite","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#website","url":"https:\/\/www.seedcapitalbizkaia.eus\/","name":"Seed Capital Bizkaia","description":"Seed Capital Bizkaia","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seedcapitalbizkaia.eus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/9f7fe51a3f998da35b8377c79e654262","name":"seed.com","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e813a261e33bb1c143e563e6a68768058e36806fb0b8bb3922b87a5100ba1926?s=96&d=mm&r=g","caption":"seed.com"},"url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/author\/seed-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/8256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/comments?post=8256"}],"version-history":[{"count":1,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/8256\/revisions"}],"predecessor-version":[{"id":8257,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/8256\/revisions\/8257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/media\/7990"}],"wp:attachment":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/media?parent=8256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/categories?post=8256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/tags?post=8256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}